The FDA's ODAC voted that the benefit-risk profile of belantamab mafodotin in multiple myeloma were not favorable, highlighting notable ocular toxicities and missed opportunities for dosing ...

This new Shingrix vaccine presentation eliminates the need for reconstitution, simplifying the administration process for ...